NasdaqGM:HROWPharmaceuticals
Harrow (HROW) Q1 Loss Of US$27.6 Million Rekindles Profitability Concerns
Harrow (HROW) Kicks Off 2026 With Mixed Top Line and a Return to Losses
Harrow (HROW) opened 2026 with Q1 revenue of US$44.2 million and a basic EPS loss of US$0.74, while trailing twelve month revenue stood at US$268.7 million and trailing EPS was a loss of US$0.40. The company has seen quarterly revenue move from US$47.8 million in Q1 2025 to US$89.1 million in Q4 2025 before landing at US$44.2 million in Q1 2026. Over the same period, EPS swung from a loss of US$0.50 in Q1 2025 to a profit...